18F-FLT PET在头颈部鳞状细胞癌患者放疗联合西妥昔单抗治疗过程中的变化
18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
作者信息
Hoeben B A W, Troost E G C, Bussink J, van Herpen C M L, Oyen W J G, Kaanders J H A M
机构信息
Bianca A.W. Hoeben, MD Radboud University Medical Center, Department of Radiation Oncology 874, P. O. Box 9101, 6500 HB Nijmegen, The Netherlands, Tel. +31/24/361 45 15; Fax +31/24/361 07 92, E-mail:
出版信息
Nuklearmedizin. 2014;53(2):60-6. doi: 10.3413/Nukmed-0625-13-09. Epub 2014 Jan 28.
AIM
Early treatment response of head and neck cancer to radiotherapy concomitant with cetuximab was monitored by repetitive PET imaging with the proliferation tracer 18F-FLT.
PATIENTS, METHODS: Five head and neck cancer patients, treated with radiotherapy and concomitant cetuximab following cetuximab induction, received four 18F-FLT PET-CT scans before and during treatment. Changes in SUVpeak, SUVmean and CT- and PET-segmented gross tumour volumes were evaluated, as were correlations with immunohistochemical staining for Epidermal Growth Factor Receptor (EGFR) and Ki-67 (proliferation marker) in pre-treatment tumour biopsies.
RESULTS
18F-FLT PET measured tumor responses to the induction dose of cetuximab varied from 43% SUVpeak decrease to 47% increase. After start of radiotherapy 18F-FLT PET parameters decreased significantly in all patients. No associations were found between PET parameters and EGFR or Ki-67 expression levels.
CONCLUSION
Proliferation of head and neck carcinomas shows a varying response to cetuximab induction, but consistently decreases after addition of radiotherapy.
目的
通过使用增殖示踪剂18F-FLT进行重复PET成像，监测头颈部癌对放疗联合西妥昔单抗治疗的早期反应。
患者、方法：5名头颈部癌患者在西妥昔单抗诱导后接受放疗及联合西妥昔单抗治疗，在治疗前及治疗期间接受了4次18F-FLT PET-CT扫描。评估了SUVpeak、SUVmean以及CT和PET分割的大体肿瘤体积的变化，以及与治疗前肿瘤活检中表皮生长因子受体（EGFR）和Ki-67（增殖标志物）免疫组化染色的相关性。
结果
18F-FLT PET测量的肿瘤对西妥昔单抗诱导剂量的反应从SUVpeak降低43%到增加47%不等。放疗开始后，所有患者的18F-FLT PET参数均显著下降。未发现PET参数与EGFR或Ki-67表达水平之间存在关联。
结论
头颈部癌的增殖对西妥昔单抗诱导表现出不同的反应，但在加用放疗后持续下降。
Zotero 插件